Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forceCindy Strehl, Frank Buttgereit, J. W. J. Bijlsma et al.|Annals of the Rheumatic Diseases|2016Cited by 331
Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysisEli M. Miloslavsky, John H. Stone, Jeffrey M. Gelfand et al.|Annals of the Rheumatic Diseases|2016Cited by 231
Barriers and potential solutions in the recruitment and retention of older patients in clinical trials—lessons learned from six large multicentre randomized controlled trialsThomas Buttgereit, Frank Buttgereit, Andriko Palmowski et al.|Age and Ageing|2021Cited by 48
The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia RheumaticaSarah Mackie, Helen Twohig, Lorna Neill et al.|The Journal of Rheumatology|2017Cited by 46
Production of IL-6 and Phagocytosis Are the Most Resilient Immune Functions in Metabolically Compromised Human MonocytesPierre-Louis Krauß, Frank Buttgereit|Frontiers in Immunology|2021Cited by 10